Microfluidic Biochips-Based Manufacturing of Personalized mRNA Cancer Therapeutics
- Automated Precision Manufacturing and on-line in-process testing with NMU-SymphonyTM
- End-to-end workflow: from RNA design to drug product in 3 weeks
- Single-use, closed-system flow path including biochips to minimize cross-contamination risks